Nuwellis, Inc. income statement
In fiscal 2025, Nuwellis, Inc. reported revenue of $8.3m, down 5.4% on the year before, operating income of −$11.1m (a -134.3% margin) and net income of −$17.5m, or −$25.39 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1 | 4 | 5 | 6 | 7 | 8 | 9 | 9 | 9 | 8 | 9 |
| Cost of revenue | — | — | — | — | — | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 3 |
| Gross profit | — | — | — | — | — | 1 | 1 | 3 | 4 | 4 | 5 | 5 | 6 | 5 | 6 |
| Research and development | 8 | 14 | 17 | 18 | 8 | 1 | 3 | 5 | 4 | 5 | 4 | 5 | 3 | 3 | 4 |
| Selling, general and administrative | 7 | 9 | 9 | 8 | 8 | 10 | 15 | 16 | 17 | 19 | 18 | 17 | 13 | 14 | 15 |
| Operating income | −15 | −23 | −26 | −26 | −16 | −15 | −17 | −18 | −17 | −20 | −17 | −18 | −11 | −11 | −13 |
| Interest expense | — | — | — | 1 | 1 | — | — | — | — | — | — | — | — | — | — |
| Income before tax | −15 | −23 | −26 | −27 | −16 | −13 | −17 | −18 | −16 | −20 | −15 | −20 | −11 | −18 | −11 |
| Income tax | −1 | −1 | −0 | −0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −14 | −22 | −26 | −27 | −16 | −13 | −17 | −18 | −16 | −20 | −15 | −20 | −11 | −18 | −11 |
| Diluted EPS | −$19174.67 | −$16559.94 | −$14623.11 | −$101476.34 | −$61808.10 | −$60527.26 | −$388.66 | −$51446.04 | −$39363.87 | −$42110.12 | −$12329.34 | −$17711.16 | −$353.30 | −$25.39 | — |
| Diluted shares (average) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −15 | −23 | −26 | −26 | −15 | −14 | −17 | −18 | −17 | −19 | −17 | −17 | −11 | −11 | −13 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Cost of revenue | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Gross profit | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 1 |
| Research and development | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Selling, general and administrative | 3 | 3 | 4 | 3 | 4 | 3 | 5 | 4 |
| Operating income | −2 | −2 | −3 | −3 | −3 | −2 | −5 | −3 |
| Income before tax | 2 | −1 | −3 | −13 | 0 | −2 | −5 | −5 |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 2 | −1 | −3 | −13 | 0 | −2 | −5 | −5 |
| Diluted EPS | $213.59 | −$17.60 | −$84.38 | −$177.85 | $6.53 | $4.71 | −$25.55 | −$26.64 |
| EBITDA | −1 | −2 | −3 | −3 | −3 | −2 | −5 | −3 |
Compare with peers
- Anbio Biotechnology income statement
- Milestone Scientific Inc. income statement
- Neuroone Medical Technologies Corp income statement
- Work Medical Technology Group LTD income statement
- Beyond Air, Inc. income statement
Head to head: NNNN vs NUWEMLSS vs NUWENMTC vs NUWENUWE vs WOK
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies